Patents matching “combination”

PT 3886798

COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF

BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Granted Apr 16, 2026 · Expires Apr 11, 2046

US 20260097057

COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS

ASTRAZENECA AB [SE] · Granted Apr 9, 2026 · Expires Apr 4, 2046

US 2025388678

Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

ASTRAZENECA AB [SE] · Granted Dec 25, 2025 · Expires Dec 20, 2045

US 12427173

Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

Biomed Valley Discoveries, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

US 12414934

Combination therapies

Aardvark Therapeutics, Inc. · Granted Sep 16, 2025 · Expires Sep 11, 2045

US 12409167

Pharmaceutical combination comprising a selective S1P1 receptor agonist

VANDA PHARMACEUTICALS INC. · Granted Sep 9, 2025 · Expires Sep 4, 2045

US 12404318

Combination HBV therapy

Vir Biotechnology, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

US 12377115

Combination immunotherapies for treatment of cancer

PrimeVax Immuno-Oncology · Granted Aug 5, 2025 · Expires Jul 31, 2045

US 12377101

Combination therapies

Mirati Therapeutics, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

CN 120418289

Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors

ASTELLAS PHARMA EUROPE B V · Granted Aug 1, 2025 · Expires Jul 27, 2045

US 12357650

Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation

Shuttle Pharmaceuticals, Inc. · Granted Jul 15, 2025 · Expires Jul 10, 2045

US 12357586

Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jul 15, 2025 · Expires Jul 10, 2045

US 12350318

Combination therapy to treat brain cancer

REGENERON PHARMACEUTICALS, INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

US 12338269

IL-2 superagonists in combination with anti-PD-1 antibodies

Medicenna Therapeutics Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

US 12336995

Combination therapies

Mirati Therapeutics, Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

US 12319738

Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

Five Prime Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

US 12318386

Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

Karyopharm Therapeutics Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

US 12280055

Combination therapies

Mirati Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

US 12281173

Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

US 12268694

Combination pharmaceutical agents as RSV inhibitors

Enanta Pharmaceuticals, Inc. · Granted Apr 8, 2025 · Expires Apr 3, 2045

US 12263173

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Cardiff Oncology, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

US 12258401

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Mar 25, 2025 · Expires Mar 20, 2045

US 12251397

Cross-linked hyaluronic acids and combinations with PRP/BMC

REGEN LAB SA · Granted Mar 18, 2025 · Expires Mar 13, 2045

US 12246064

Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

Takeda Pharmaceutical Company Limited · Granted Mar 11, 2025 · Expires Mar 6, 2045